Cargando…
Efficacy and Tolerability of the Association of Sibutramine and Orlistat for Six Months in Overweight and Obese Patients
Objective. To assess the efficacy and tolerability of the association sibutramine (10–20 mg/day) and orlistat (120 mg 2-3 times a day) in the treatment of obesity in a six-month open trial. Methods. 446 overweight and obese patients who sought treatment for obesity in a private clinic were assessed...
Autores principales: | Halpern, Alfredo, Pepe, Renata B., Monegaglia, Ana Paola, Beyruti, Mônica, de Melo, Maria Edna, Mancini, Marcio C. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2943097/ https://www.ncbi.nlm.nih.gov/pubmed/20871858 http://dx.doi.org/10.1155/2010/602537 |
Ejemplares similares
-
Orlistat in the prevention of diabetes in the obese patient
por: Mancini, Marcio C, et al.
Publicado: (2008) -
The effectiveness of pharmaceutical interventions for obesity: weight loss with orlistat and sibutramine in a United Kingdom population-based cohort
por: Douglas, Ian J, et al.
Publicado: (2015) -
Comparative effects of sibutramine and orlistat on weight loss, glucose metabolism and leptin levels in non-diabetic obese patients: A prospective study
por: Anagnostis, Panagiotis, et al.
Publicado: (2012) -
Sibutramine on Cardiovascular Outcome
por: Scheen, André J.
Publicado: (2011) -
Combination of the sodium-glucose cotransporter-2 inhibitor empagliflozin with orlistat or sibutramine further improves the body-weight reduction and glucose homeostasis of obese rats fed a cafeteria diet
por: Vickers, Steven P, et al.
Publicado: (2014)